<DOC>
	<DOC>NCT01846650</DOC>
	<brief_summary>1. purpose: To conduct the relative bioavalability study of Capecitabine tablets 500 mg (Jiangsu Chia-Tai Tianqing Pharmacy Co. Ltd.) versus XELODA® 500 mg tablets (Manufactured by Roche Pharma AG) 2. Experimental Design： Two-period crossover design 3. Test drug: Capecitabine tablets Reference drug: XELODA 4. Sample size：24</brief_summary>
	<brief_title>A Bioequivalence Study of Capecitabine Tablets</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Patients must have histopathologically /cytologically confirmed breast cancer or colorectal cancer，without chemotherapy or only adjuvant chemotherapy, and had previously received one or two standard chemotherapy regimens for patients; Age: 1870 years, gender: both，BMI≥17，Eastern Cooperative Oncology Group (ECOG) performance status：02，Life expectancy greater than 3 months; Patients must have normal bone marrow function, liver and kidney function; adequate organ function in the last 1 week, meeting the following: ANC≥1.5×109/L，PLT≥80×109/L, Total bilirubin≤1.5×the upper limit of normal, ALT,AST≤2.5×the upper limit of normal, creatinine≤1.5×the institutional upper limit of normal. Patients who has retreatment could be enrolled at least 4 weeks after the last chemotherapy and radiotherapy. Patients must volunteer to participate and sign informed consent form. Suffering from heart, liver, kidney disease or severe acute and Organ invasion disease; Prior unanticipated severe reaction to fluoropyrimidine therapy, or known sensitivity to 5fluorouracil, or known DPD (Dihydropyrimidine Dehydrogenase) deficiency. Pregnant or breastfeeding female Only bone metastasis lesions, no other measurable lesions Known brain metastasis or history of organ transplantation Have longterm systemic steroid therapy Serious diseases of vital organs; other malignancies which is not cure Use of chemotherapy in the last 4 weeks History of drug/alcohol addiction or a positive hepatitis screen including hepatitis B surface antigen, HCV or HAV (IgM) antibodies Patient having abnormal serum calcium level at screening visit which as judged by Investigator could lead to safety risk to the patient upon participation in the trial or could interfere with the conduct of the trial. Preexisting motor or sensory neurotoxicity of a severity grade 2 by NCI CTCAE criteria or known, existing uncontrolled coagulopathy. Subjects are thought unsuitable for the study by investigators; Inability to comply with protocol or study procedures in the opinion of the investigator;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>